Renoprotective effect of additional sodium–glucose cotransporter 2 inhibitor therapy in type 2 diabetes patients with rapid decline and preserved renal function

The slope of estimated glomerular filtration rate (eGFR) decline (eGFR slope) in early-stage type 2 diabetes patients might predict the future risk of end-stage renal disease. Type 2 diabetes patients who show rapid progressive eGFR decline are termed rapid decliners. Several studies of rapid decliners have investigated the efficacy of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with advanced renal dysfunction; however, no studies, to our knowledge, have focused on patients with preserved renal function. Therefore, we investigated the efficacy of SGLT2i in rapid decliners with preserved renal function.This study enrolled type 2 diabetes patients with baseline eGFR ≥60 mL/min/1.73 mAmong 165 patients treated with SGLT2i for ≥3 years, 21 patients were rapid decliners with preserved renal function. The mean age and eGFR at SGLT2i administration were 58.6 years and 87.1 mL/min/1.73 mEarly intervention with SGLT2i may have renoprotective effects in type 2 diabetes patients with rapid decline and preserved renal function.